Body Handbook Catalogue Profile Ranking
Healthcare BODY HANDBOOK
Healthcare Β· Β§644
Polycystic Ovary Syndrome (PCOS)
PCOS is the most common hormonal condition in women of reproductive age, and it gets filed as a fertility problem that stops mattering once children are settled. That framing is the danger. It is a lifelong metabolic condition that roughly triples your odds of type 2 diabetes and quietly raises heart, liver, sleep and mood risk for decades, showing up years before anyone names it. Catching it early is one of the highest-leverage health moves a woman can make.
Condition Evidence Moderate Chapter Healthcare

Insulin resistance is the engine: it drives the ovary to overproduce androgens, which stalls ovulation. And it's only partly about weight, since women with PCOS run about a quarter less insulin-sensitive than same-weight women without it 1. That's why slim PCOS is real, and why it gets missed.

Diagnosis is now a blood test. The rule is two of three: irregular cycles (over 35 days apart, past the teens), signs of high androgens (chin hair, jawline acne, or high testosterone), and the ovary look on ultrasound. The 2023 change: in adults, an anti-MΓΌllerian hormone (AMH) blood draw now replaces the ultrasound 2. No gynaecology referral, no scan needed.

The costs arrive on a schedule. Twenties: skin, hair and cycles read as personal failure, and depression runs high 3. Thirties: harder conception, riskier pregnancies. Forties: type 2 diabetes at about 2.9 times background 4. Fifties on: heart disease and stroke about 1.4 times higher 5, enough that cardiology now starts blood-pressure and cholesterol drugs earlier 6.

Three companions almost nobody screens for: sleep apnoea (35–40% versus 6% 7), fatty liver (40–50% 8), and, after years of few periods, roughly three-fold endometrial cancer risk 9.

What to ask for, in order:

What changes once you engage. First the reframe: a decade of separate stories become one diagnosable thing. Cycles run predictably within two to three months on the pill, jawline acne fades by six. The metabolic win is invisible and the biggest: annual screening plus a few per cent weight loss bend the diabetes curve down, so catching this at 25 can leave you at fifty looking like someone who never had it.

The fine print β€” when to skip it, and what people get wrong

"Polycystic" isn't dangerous cysts; they're stalled follicles needing no surgery. It is not only a disease of overweight women. And it does not end at menopause: cycles stop mattering, the metabolic risk keeps climbing.

Anti-androgens like spironolactone are teratogenic, so contraception is mandatory alongside them. Metformin and GLP-1 drugs aren't just for weight; dropping them when the scale stalls misreads their job.

References
  1. 1Cassar et al. (2016). Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Human Reproduction. link
  2. 2Teede et al. (2023). Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology & Metabolism. link
  3. 3Cooney et al. (2017). High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction. link
  4. 4Glintborg et al. (2024). Prospective risk of Type 2 diabetes in 99,892 Nordic women with polycystic ovary syndrome and 446,055 controls: national cohort study from Denmark, Finland, and Sweden. Human Reproduction. link
  5. 5Wekker et al. (2020). Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Human Reproduction Update. link
  6. 6Carmina E, Lobo RA (2022). Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease. Fertility and Sterility. link
  7. 7Kahal et al. (2020). The prevalence of obstructive sleep apnoea in women with polycystic ovary syndrome: a systematic review and meta-analysis. Sleep and Breathing. link
  8. 8Rocha et al. (2017). Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. Journal of Endocrinological Investigation. link
  9. 9Barry et al. (2014). Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update. link
  10. 10Legro et al. (2014). Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. New England Journal of Medicine. link
Β·
644